<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40818652</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-3871</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Heart rhythm</Title><ISOAbbreviation>Heart Rhythm</ISOAbbreviation></Journal><ArticleTitle>Catheter ablation vs antiarrhythmic drug therapy for first-line treatment of atrial fibrillation in United States clinical practice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1547-5271(25)02758-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hrthm.2025.07.061</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Catheter ablation (CA) has a Class I indication for first-line rhythm control for atrial fibrillation (AF).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to compare the safety and effectiveness of CA vs antiarrhythmic drug (AAD) for first-line rhythm control therapy in clinical practice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Persons with incident AF (2015-2022) in the Optum Clinformatics cohort were categorized by the first-line treatment they received (CA or AAD). The incidence of hospitalization for atrial arrhythmia (AF, atrial flutter, or tachycardia) at 1-year (3-month blanking period) was compared between CA and AAD. Cox regression with inverse probability of treatment weighting was used to compare outcomes between treatment groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 2711 CA-treated (mean age 66.4 &#xb1; 10.7 years, 39.8% woman) and 22,726 AAD-treated (mean age 70.3 &#xb1; 11.4 years, 52.2% woman) persons with a new diagnosis of AF were included. Patients undergoing CA as the first-line therapy had a 48% lower risk (adjusted hazard ratio [HR] = 0.52, 95% confidence interval [CI] 0.40-0.68) of hospitalization for atrial arrhythmia, a 52% lower risk of AF-related electrical cardioversion (HR = 0.48, 95% CI 0.34-0.68), and a 74% lower risk of hospitalization for heart failure (HR = 0.26, 95% CI 0.13-0.54) compared with those receiving first-line AAD therapy. Lower risks of atrial arrhythmia hospitalization were also found with first-line CA receipt vs AAD in paroxysmal (HR = 0.52, 95% CI 0.37-0.73) and persistent AF (HR = 0.55, 95% CI 0.37-0.81).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">First-line CA for both paroxysmal and persistent AF is associated with significantly lower risk of hospitalization for atrial arrhythmia consistent with results from randomized clinical trials and current Class I guideline recommendations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pimentel</LastName><ForeName>Rhea C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>XXX, The University of Kansas Health System, Kansas City, Kansas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanna</LastName><ForeName>Rahul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>XXX, MedTech Epidemiology and Real-World Data Sciences, Johnson &amp; Johnson, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maccioni</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>XXX, Johnson &amp; Johnson Medical Devices, Franchise Health Economics and Market Access, Irvine, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dongyu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>XXX, MedTech Epidemiology and Real-World Data Sciences, Johnson &amp; Johnson, New Brunswick, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccini</LastName><ForeName>Jonathan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Electrophysiology Section, Duke Heart Center, Duke University Hospital &amp; Duke Clinical Research Institute, Durham, North Carolina. Electronic address: jonathan.piccini@duke.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Heart Rhythm</MedlineTA><NlmUniqueID>101200317</NlmUniqueID><ISSNLinking>1547-5271</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiarrhythmic drug</Keyword><Keyword MajorTopicYN="N">Atrial fibrillation</Keyword><Keyword MajorTopicYN="N">Catheter ablation</Keyword><Keyword MajorTopicYN="N">First-line therapy</Keyword><Keyword MajorTopicYN="N">Retrospective database</Keyword></KeywordList><CoiStatement>Disclosures Rhea C. Pimentel has no conflict of interest to declare. Rahul Khanna, Sonia Maccioni, and Dongyu Zhang are employees of Johnson &amp; Johnson. Jon P. Piccini is supported by R01AG074185 from the National Institutes of Aging; he also receives grants for clinical research from Abbott, the American Heart Association, Boston Scientific, iRhythm, and Philips and serves as a consultant to Abbott, Boston Scientific, Kardium, Medtronic, Milestone Pharmaceuticals, Sanofi, SymKardia, Philips, and Up-to-Date.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>17</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>17</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>16</Day><Hour>19</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40818652</ArticleId><ArticleId IdType="doi">10.1016/j.hrthm.2025.07.061</ArticleId><ArticleId IdType="pii">S1547-5271(25)02758-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>